[{"address1": "116 Huntington Avenue", "address2": "Suite 703", "city": "Boston", "state": "MA", "zip": "02116", "country": "United States", "phone": "617 468 4219", "website": "https://www.bicara.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.", "companyOfficers": [{"maxAge": 1, "name": "Ms. Claire  Mazumdar Clemon M.B.A., Ph.D.", "age": 34, "title": "CEO & Director", "yearBorn": 1989, "fiscalYear": 2023, "totalPay": 650000, "exercisedValue": 0, "unexercisedValue": 578357}, {"maxAge": 1, "name": "Mr. Ryan  Cohlhepp Pharm.D.", "age": 47, "title": "President, COO & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 660000, "exercisedValue": 0, "unexercisedValue": 103783}, {"maxAge": 1, "name": "Mr. Ivan  Hyep M.B.A.", "age": 39, "title": "Chief Financial Officer", "yearBorn": 1984, "fiscalYear": 2023, "totalPay": 597500, "exercisedValue": 0, "unexercisedValue": 77109}, {"maxAge": 1, "name": "Ms. Lara S. Meisner J.D.", "age": 51, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rachel  Salazar", "title": "SVP of R&D Strategy and Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sathish  Hasige Ph.D.", "title": "Senior VP and Head of Technical Operations & Supply Chain", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Raben M.D.", "age": 60, "title": "Chief Medical Officer", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Angela  Windt", "title": "VP & Head of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jeltje  Schulten M.B.A., M.D.", "title": "Senior Vice President of Clinical & Medical Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jean-Paul  Rodrique", "title": "Senior VP & Global Head of Quality Assurance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 19.12, "open": 18.94, "dayLow": 17.875, "dayHigh": 19.21, "regularMarketPreviousClose": 19.12, "regularMarketOpen": 18.94, "regularMarketDayLow": 17.875, "regularMarketDayHigh": 19.21, "forwardPE": -12.40048, "volume": 283088, "regularMarketVolume": 283088, "averageVolume": 426919, "averageVolume10days": 849350, "averageDailyVolume10Day": 849350, "bid": 18.22, "ask": 18.31, "bidSize": 400, "askSize": 400, "marketCap": 994173056, "fiftyTwoWeekLow": 16.01, "fiftyTwoWeekHigh": 28.09, "fiftyDayAverage": 20.7, "twoHundredDayAverage": 21.668783, "currency": "USD", "enterpriseValue": 436753760, "floatShares": 31521176, "sharesOutstanding": 54415600, "sharesShort": 2347100, "sharesShortPriorMonth": 1690473, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.0431, "heldPercentInsiders": 0.06262, "heldPercentInstitutions": 0.67155, "shortRatio": 7.26, "impliedSharesOutstanding": 54415600, "bookValue": 9.365, "priceToBook": 1.950881, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -59478000, "trailingEps": -1.09, "forwardEps": -1.61, "enterpriseToEbitda": -6.295, "52WeekChange": -0.21956426, "SandP52WeekChange": 0.25891924, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "BCAX", "underlyingSymbol": "BCAX", "shortName": "Bicara Therapeutics Inc.", "longName": "Bicara Therapeutics Inc.", "firstTradeDateEpochUtc": 1726234200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "89c17e6e-41f3-3d01-85f9-cd0e48aa9b6d", "messageBoardId": "finmb_674698236", "gmtOffSetMilliseconds": -18000000, "currentPrice": 18.27, "targetHighPrice": 47.0, "targetLowPrice": 36.0, "targetMeanPrice": 40.5475, "targetMedianPrice": 39.595, "recommendationKey": "none", "numberOfAnalystOpinions": 4, "totalCash": 520758016, "totalCashPerShare": 9.571, "ebitda": -69384000, "totalDebt": 445000, "quickRatio": 35.961, "currentRatio": 36.014, "debtToEquity": 0.087, "operatingCashflow": -52755000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-28"}]